Disorders of phosphate metabolism are common complications in dialyzed patients, and control of serum phosphorus seems to be a critical factor in the survival of these patients. In several studies, a tight association has been observed between elevated serum phosphorus and mortality (1, 2) .
Regulation of phosphate homeostasis in chronic kidney disease (CKD) is controlled by a variety of factors, such as phosphate loading and serum calcium, vitamin D and parathyroid hormone (PTH). In peritoneal dialysis (PD), elimination of phosphate depends on peritoneal and renal phosphate clearance [the latter clearance depending on residual renal function (RRF)]. Recently, high serum levels of fibroblast growth factor 23 (FGF-23) have been regarded as independent factor associated with morbidity and mortality in dialyzed patients (3) (4) (5) (6) . In patients with CKD, circulating FGF-23 gradually increases with declining renal function. Isakova et al. (7) suggested that FGF-23 might be a sensitive early biomarker of disordered phosphorus metabolism in patients with CKD and a normal phosphate level, because FGF-23 increases earlier than either phosphate or PTH. However, the clinical significance of FGF-23 measurement in PD patients has not yet been fully established.
A recent study of ours (8) suggests that serum phosphate may be associated with peritoneal membrane transport in incident PD patients. The aim of the present study, conducted in a larger cohort of subjects, was to more thoroughly evaluate associations between regulators of phosphate metabolism (including FGF-23) and phosphate concentrations and clearances at the onset of PD.
METHODS
At the Peritoneal Dialysis Center, Department of Nephrology, Transplantology and Internal Medicine, Szczecin, Poland, 50 patients were started on continuous ambulatory PD using 4 daily exchanges of 1.5 -2 L glucose-based dialysate with a calcium concentration of 1.25 mmol/L (Baxter Healthcare SA, Castlebar, Ireland). All patients gave written informed consent, and the study was approved by the local bioethics committee. Peritoneal and renal clearances of creatinine and phosphorus were calculated by means of direct determination from dialysis fluids, urine, and serum. Serum levels of FGF-23 were determined using a sandwich enzyme-linked immunosorbent assay (Human FGF-23 ELISA Kit: Millipore Corporation, Bedford, MA, USA). Table 1 presents the main characteristics of the study group. The causes of end-stage renal disease were diabetes (n = 6), glomerulonephritis (n = 12), hypertension (n = 10), chronic pyelonephritis (n = 3), other (n = 10), and unknown (n = 9).
The Spearman rank correlation coefficient (R s ) was used to measure associations between quantitative variables. We observed a strong positive correlation between serum phosphorus and FGF-23 (R s = 0.54, p = 0.00085, Figure 1 ). Table 2 presents the associations of serum phosphorus, PTH, and FGF-23 with parameters of PD and RRF in patients at the onset of PD.
Renal phosphate clearance was strongly negatively correlated with serum phosphorus (R s = -0.51, p = 0.003), but not with serum FGF-23 (R s = -0.26, p = 0.19).
Multivariate analysis using the log of serum FGF-23 as the dependent variable and the log of serum phosphate and the RRF as independent variables showed that, in patients at the onset of PD, a high phosphate concentration is an independent determinant of high serum FGF-23 (β = 0.53, p = 0.0028), independent of low RRF (β = -0.15, p = 0.36). 
DISCUSSION
Of PD patients overall, 40% -50% are estimated to have serum phosphate concentrations exceeding 1.8 mmol/L (9). In the present study, the prevalence of hyperphosphatemia was 28%, which is consistent with a study of 264 continuous ambulatory PD patients by Bernardo et al. (10) in which the prevalence reached 30% and, after 1 year of PD treatment, serum phosphate correlated negatively with RRF and renal phosphate clearance. We also observed negative correlations between serum phosphorus and renal phosphate clearance, which may underline the important role of RRF in phosphate metabolism at the beginning of PD therapy.
The main physiologic role of FGF-23 in healthy subjects is to increase urinary phosphate excretion to maintain stable levels of serum phosphate. The increase in FGF-23 starts at a very early stage of CKD in an attempt to stabilize serum phosphate as the number of intact nephrons declines. Several studies showed that increased serum FGF-23 was associated with increased cardiovascular risk and mortality in dialyzed patients (3, 11) . In a group of patients starting hemodialysis, Gutiérrez et al. (11) found a strong relationship between high serum FGF-23 and an increased risk for 1-year mortality. Interestingly, in that population, FGF-23 was a stronger predictor of mortality than serum phosphorus was. Other studies showed that serum FGF-23 is related to the prevalence of left ventricular hypertrophy in patients with CKD (12, 13) . In a study by Faul et al. (14) , the authors reported that serum FGF-23 was independently associated with left ventricular hypertrophy in a large, racially diverse CKD cohort. Interestingly, studies on mice disclosed that the pathogenesis of left ventricular hypertrophy attributable to the action of FGF-23 had a klothoindependent mechanism.
In the PD patient population, data on FGF-23 are scarce. In a study by Isakova et al. (15) , performed in 67 adult PD patients, the authors found that longer dialysis vintage (R = 0.31), lesser RRF (R = -0.37), and lower renal phosphate clearance (R = -0.38) were associated with higher levels of serum FGF-23. In a study performed in 35 incident PD patients, Viaene et al. (16) showed that declining renal function was inversely correlated with serum FGF-23. Those authors also observed a significant increase in serum phosphorus with the decline of RRF.
In the present study of incident PD patients, we found strong correlations between FGF-23 and RRF and between FGF-23 and serum phosphorus. Moreover, in multivariate analysis, we found that a high phosphorus concentration was a significant predictor of high FGF-23, independent of RRF. It seems possible that increased serum phosphorus is directly responsible for increased serum FGF-23, and that the influence of RRF is indirect (mediated by an increased phosphorus concentration). In our study, neither renal nor peritoneal phosphate clearance was associated with serum FGF-23, potentially suggesting that the influence of phosphate elimination on FGF-23 in incident PD patients is also indirect (mediated by serum phosphorus concentration).
To the best of our knowledge, we are the first to report the strong association between serum phosphorus and FGF-23, independent of RRF, in incident PD patients. Because increased serum FGF-23 can be independently associated with higher morbidity and mortality, it seems that, even in a group of incident PD patients without marked hyperphosphatemia, control of serum phosphate may bring benefits and improve outcomes.
CONCLUSIONS
Our study highlights the strong positive association between serum phosphorus and FGF-23 in patients at the start of PD therapy. This relationship is independent of RRF. Moreover, renal and peritoneal phosphate elimination are not associated with serum FGF-23. Because, by itself, increased FGF-23 may be associated with increased morbidity, further studies of FGF-23 as a potential target for clinical intervention are awaited.
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